A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

IRB/UVA Tracking #
19861
Contact First Name

Erica Stallard

Contact Email
Phase
III
Primary purpose
Treatment
Cancer PI
Craig Portell
Status
OPEN TO ACCRUAL